press releases

Half-Year report on the liquidity contract signed by Lysogene with Kepler Cheuvreux

Half-Year report on the liquidity contract signed by Lysogene with Kepler Cheuvreux 150 150 Lysogene

Paris, France — 15 January 2021 at 06:00pm — Lysogene (FR0013233475 – LYS), a phase…

Lysogene Receives MHRA and Research Ethics Committee Approvals to Initiate the Gene Therapy Clinical Trial in the UK with LYS-GM101 for the Treatment of GM1 Gangliosidosis

Lysogene Receives MHRA and Research Ethics Committee Approvals to Initiate the Gene Therapy Clinical Trial in the UK with LYS-GM101 for the Treatment of GM1 Gangliosidosis 150 150 Lysogene

LYS-GM101 is Lysogene’s second CNS gene therapy program to enter clinic

Lysogene Reports First Half 2020 Financial Results and Provides Operational Update

Lysogene Reports First Half 2020 Financial Results and Provides Operational Update 150 150 Lysogene

Cash position of €23.8m as of 30 June 2020 strengthened by a €7.7m capital increase ledby OrbiMed and Sarepta, extending cash runway to Q4 2021

Lysogene: First Half 2020 Business Update

Lysogene: First Half 2020 Business Update 150 150 Lysogene

Cash and cash equivalent of €23.8 million1 as of 30 June 2020 FDA letter on…

Lysogene announces a research collaboration with the Weizmann Institute of Science

Lysogene announces a research collaboration with the Weizmann Institute of Science 150 150 Lysogene

Novel AAV gene therapy approach for neuronopathic Gaucher disease and Parkinson disease with GBA1 mutations…

LYSOGENE releases the results from June 26, 2020 ordinary annual and extraordinary general meeting

LYSOGENE releases the results from June 26, 2020 ordinary annual and extraordinary general meeting 150 150 Lysogene

Shareholders approved all proposed resolutions Paris, France — 26 June 2020 — Lysogene (FR0013233475-LYS) held…

Lysogene announces important updates on AAVance phase 2/3 clinical trial with LYS-SAF302 in MPS IIIA

Lysogene announces important updates on AAVance phase 2/3 clinical trial with LYS-SAF302 in MPS IIIA 150 150 Lysogene

Paris, France — 05 June 2020 at 08:00am CEST— Lysogene (FR0013233475 – LYS), a Phase…

NOVASEP and LYSOGENE Announce their New Collaboration for Development and Production of GM1 Gangliosidosis Gene Therapy Product This agreement covers the manufacturing of the Adeno-Associated Virus (AAV)

NOVASEP and LYSOGENE Announce their New Collaboration for Development and Production of GM1 Gangliosidosis Gene Therapy Product This agreement covers the manufacturing of the Adeno-Associated Virus (AAV) 150 150 Lysogene

Lyon and Paris, France, May 26, 2020 – Novasep, a leading supplier of services and…

LYSOGENE Annual Ordinary and Extraordinary General Meeting of 26 June 2020 Availability of the Preparatory Documents

LYSOGENE Annual Ordinary and Extraordinary General Meeting of 26 June 2020 Availability of the Preparatory Documents 150 150 Lysogene

Paris, France — 20 May 2020 at 06:00pm CEST— Lysogene (FR0013233475 – LYS), a Phase…

Lysogene Announces Presentations at Upcoming Meetings:

Lysogene Announces Presentations at Upcoming Meetings: 150 150 Lysogene

2020 American Society of Gene & Cell Therapy Annual (ASGCT) virtual Meeting European Forum for…

Lysogene COVID-19 update

Get In Touch

Don’t hesitate to contact us if you need more help.